Although pancreatic neuroendocrine tumours (PETs) are rare, autopsy series have revealed a high incidence ranging from 0.8 to 10%, reflecting their relative lack of progression and low malignant potential (Kaltsas et al. 2004) . Following the application of current sensitive imaging modalities, it is highly probable that the identification of such lesions will increase (Bruzoni et al. 2008) . Although biochemical and/or imaging modalities may help differentiate them from evolving adenocarcinoma, histological confirmation remains the definitive diagnostic procedure. Fine needle aspiration and biopsy (FNAB) of pancreatic lesions can be easily performed during endoscopic ultrasonography (EUS), allowing for the preoperative cytological characterisation of such lesions and the estimation of biological behaviour through Ki-67 labelling index (LI) estimation (Kaltsas et al. 2004) . To date, only one study has compared the EUS-FNAB cytological Ki-67LI estimation in 18 patients with surgically obtained histological Ki-67LI, demonstrating an overall good agreement, particularly with low Ki-67LI values (Piani et al. 2008) .
This relative paucity of data prompted us to review 26 patients who had cytological and histological Ki-67LI estimation. All EUS-FNAB procedures were performed by the same operator and evaluated by the same cytologist. All histological samples were reviewed by one pathologist who also reviewed in a blind manner the cytological specimens to delineate the level of concordance between cytologist and pathologist. Comparison was based on the WHO 2010 grading system (Bosman et al. 2010) using the k-statistic. The cytological assessment of the Ki-67LI revealed that 15 (58%) of tumours could be classified as G1, nine (34%) as G2 and two (8%) as G3. The histological assessment of the surgical samples classified 11 (42%) tumours as G1, 13 (50%) as G2 and two (8%) as G3 (Table 1 ). An agreement between the cytological and the histological Ki-67LI expression was found in 7/11 (64%) patients with G1, 5/13 (38%) with G2 and 2/2 (100%) with G3 tumours. The overall agreement between EUS-FNAB and histological Ki-67LI expression was 54% (14/26). The k-statistic was 0.08 indicating poor agreement, whereas interobserver variation between cytologist and pathologist was 0.96.
Based on these findings in our 26 patients, a complete agreement between EUS-FNAB and histologically obtained Ki-67LI estimation was found only in patients with a Ki-67LI O20% (G3 tumours). In contrast, there was a low overall agreement (54%) when Ki-67LI cut-off values of %2 and 3-20 were considered, even though a limitation of our study was that only two patients had a Ki-67LI O20%. Our findings suggest that it would have been misleading to rely only on EUS-FNAB obtained Ki-67LI, as 12/26 (46%) patients would have been misclassified as having tumours of either lower (8) or higher (4) malignant potential. These findings are different to that of the initial study that demonstrated 89% agreement between cytological and histological measurement using a Ki-67LI cut-off value of 2%. As most PETs are well differentiated, it was concluded that it would be safe to characterise correctly such patients only on EUS-FNAB samples. This was based on data showing that patients with a histologically obtained Ki-67LI of O 2% exhibit greater mortality and lower 5 year survival than those with a Ki-67LI of %2 (Kaltsas et al. 2004 ). However, based on the results of our study, 46% of the 26 patients would have been misclassified. This poor concordance of cytological and histological Ki-67LI values could be due to the approximate quantitative estimation of the Ki-67LI in FNAB samples and intratumoural cellular heterogeneity. However, EUS-FNAB remains a powerful means of characterising the neuroendocrine nature of these tumours.
As the number of incidentally discovered pancreatic lesions is likely to increase, the clinical implication of this study lies in the relatively low diagnostic EUS-FNAB accuracy in assessing the biological behaviour of such lesions. This is particularly important as lesions %2 cm with a FNAB Ki-67LI of %2 cannot be considered as WHO-class I tumours with relatively benign behaviour amenable to follow-up. We suggest that EUS-FNAB should be used in the pre-operative assessment of patients with PETs to establish the diagnosis, but further studies including a larger number of patients are needed to evaluate its role as a predictive tool for the biological behaviour and prognosis of PETs.
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